To the Editor Espay and Lang1 present a thought provoking Viewpoint regarding levodopa therapy in Parkinson disease (PD).1 We respectfully submit that its subtitle “When Clinical Trials Misinform Clinical Practice” is not justified. If levodopa has come into disrepute in the past, and dopamine agonist monotherapy has been left unsupplemented by levodopa for too long, this is not because of misinformation that was provided by the comparative clinical trials themselves, but rather by the inadequate translation of study results into clinical practice.
Lim S, Poewe W, Tan AH. Levodopa and Parkinson Disease—Myths Revisited. JAMA Neurol. 2017;74(10):1270. doi:10.1001/jamaneurol.2017.2560
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: